FDA approves Vowst as first oral microbiota biotherapeutic for recurrent C. difficile

The FDA has approved Vowst, the first orally administered fecal microbiota product indicated for the prevention of recurrent Clostridioides difficile infection in adults following antibacterial treatment.With this approval, Vowst ( SER-109, Seres Therapeutics) becomes the second microbiota-based live biotherapeutic approved for recurrent C. difficile infection following the approval of Rebyota (fecal microbiota, live-jslm; Ferring Pharmaceuticals) in 2022.“Today’s approval provides patients and health care providers a new way to help prevent recurrent C. difficile infection,”Read More